Leveraging cross-linking

How Lyvgen is leveraging FCGR2B to enhance tumor selectivity of its cancer mAbs

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs.

According to founder and CEO Jieyi Wang, mAbs in clinical development that agonize co-stimulatory molecules, such as CD40 and TNF receptor superfamily member 9 (4-1BB; TNFRSF9; CD137), were primarily discovered by screening for strong agonism of the co-stimulatory receptors but

Read the full 704 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE